Data from a meta-analysis study of Mederi Therapeutics Stretta device released this week indicate that treatments with the device reduced heartburn and improved health-related quality of life scores for patients with gastroesophageal reflux disease. The company’s Stretta catheter system applies low-power radio frequency energy to remodel the lower esophageal sphincter to restore natural barrier function […]
NORWALK, CT – Mederi Therapeutics Inc. today announced two milestones in the worldwide growth of Stretta Therapy for GERD, which include the completion of the 18,000th Stretta procedure and new regulatory approvals in OUS markets of Mexico, India, South Africa, Australia, Argentina and South Korea.
NORWALK, Conn. — A newly published, pathologist-blinded study in a porcine model, examines the histopathology changes after non-ablative radiofrequency (NARF) to smooth muscle as delivered by Stretta therapy for GERD and Secca therapy for fecal incontinence. Radiofrequency therapy is commonly thought of in terms of ablation, where tissue destruction occurs.
Connecticut-based Mederi Therapeutics closed a Series B financing round, bringing in $18.5 million through sales of preferred stock and venture debt.
Funding was led by Acadia Woods Partners, LLC, Respiratory Diagnostics Inc., and Horizon Technology Finance, Mederi reported.
Here’s a roundup of companies announcing clearances and approvals from the Food & Drug Administration and foreign regulatory agencies:
Ten years after it first won clearance from the Food & Drug Administration, Mederi Therapeutics Inc.’s Stretta treatment for gastro-esophageal reflux disease is hitting the market in the U.S.